anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method of manufacturing a composition in which an ultraviolet ray shielding effect or Sun Protection Factor (hereinafter called SPF) is improved by a little ultraviolet defense agent, and the emulsion condition is stabilized in a cosmetic or a dermatological quasi drug formulation which has an ultraviolet ray shielding effect.  &lt;P&gt;SOLUTION: The formulation includes combining, with a specific compounding ratio, each of: a powder which has an ultraviolet ray shielding effect; an ultraviolet ray shielding agent which contains at least one kinds of organic based ultraviolet absorbers; water; an oil; and an emulsifier. The composition of a cosmetic or a dermatological quasi drug formulation which has an ultraviolet ray shielding effect (SPF) and the manufacturing therefor includes as follows. A treatment liquid is held into a container at a manufacturing process. In a stirring method which rotates a stirring implement in the treatment liquid, and agitates the treatment liquid, the high-speed stirring of the stirring implement with an end arriving at the proximity of the inner peripheral surface of the container is carried out in the treatment liquid, the stirring implement agitates at the end of stirring implement, making the treatment liquid rotate by a hollow membrane while making the treatment liquid stick to the container inside surface by pressure with a centrifugal force by the rotation of the treatment liquid accompanying with the rotation of the stirring implement, in this way a thin film rotation type high speed stirring is performed (for example T.K. FILMIX is used), thereby a dispersed state and an emulsion condition of the powder are stabilized.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The invention relates to a recombinant Lactobacillus strain, with limited growth and viability in the environment. More particularly, it relates to a recombinant Lactobacillus that can only survive in a medium, where thymidine is present. By this strict dependency upon thymidine, thymidine less death is rapidly induced in this recombinant strain. A preferred embodiment is a Lactobacillus that may only survive in a host organism, where thymidine is present, but cannot survive outside the host organism in absence of this medium compound. Moreover, said Lactobacillus strain can be transformed with prophylactic and/or therapeutic molecules and can, as such, be used to treat diseases such as, but not limited to, inflammatory bowel diseases. ® KIPO &amp; WIPO 2007
1,168,917. Pharmaceutical compositions. SMITH KLINE &amp; FRENCH LABORATORIES. 25 May, 1967 [27 June, 1966], No, 24466/67. Heading A5B. A pharmaceutical composition which ameliorates the effects of and prevents influenza infections comprises an effective but non- toxic amount of α-methylcyclohexanemethylamine or α. α-dimethylcyclohexanemethylamine or a pharmaceutically acceptable acid addition salt thereof e.g. with hydrochloric, sulphuric, hydrobromic and maleic acids, and a pharmaceutical non-toxic carrier. The compositions may be administeredorally in the form of capsules which may be in a sustained release form, tablets or syrups or intranasally as a spray or drops containing 2-10% by weight of the active compound.
PURPOSE:To obtain a preventive and treating agent of ischemia re-perfusion disorder effective for preventing and treating myocardial infarction and arrhythmia after natural pantency caused by cardiac coronary occlusion, comprising a specific sulfonanilide compound and a salt as active ingredients. CONSTITUTION:A preventive and treating agent for ischemia re-perfusion disorder comprising a compound shown by formula I (R&lt;2&gt; is lower alkyl; R&lt;2&gt; is lower alkanoyl, carbamoyl, cyano, etc.; R&lt;3&gt; is H or R&lt;2&gt; and R&lt;3&gt; together with C form ring shown by formula II; R&lt;4&gt; and R&lt;5&gt; are H or halogen; X is O or S) and a salt (e.g. lithium salt or sodium salt) as active ingredients. The compound shown by formula I is effectively used with an immunosuppressive agent in organ transplantation. A daily dose of the compound shown by formula I is 0.5-1,000mg, preferably 1-500mg usually by oral administration.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a diagnostic imaging support system etc. which can appropriately transmit to a client apparatus which requires medical information to be represented by a shared object etc. so as not to deteriorate at least one efficiency among communication efficiency in a network, operation efficiency in respective apparatuses and work efficiency in diagnostic reading, the whole or a part of the contents of the medical information.  &lt;P&gt;SOLUTION: A server device, for example, judges an information section based on a user and a usage scene, and judges proved information based on the judged information section. The shared object is processed so as to include only the judged provision information, and then, provided to the client apparatus. The shared object including only required minimum information is provided to the client apparatus.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To obtain a vitamin D pharmaceutical, containing vitamin D and acid-soluble polymers, improved in stability of the vitamin D and preservable for a long period. CONSTITUTION:The objective substance is obtained by homogeneously mixing vitamin D (e.g. vitamin D2 or vitamin D3) with acid-soluble polymers (e.g. an aminoalkyl methacrylate copolymer B), as necessary, blending normally used pharmaceutical additives with the aforementioned ingredients and preparing a pharmaceutical according to a conventional method. The above-mentioned substance can be prepared into the form of powder, granule, granule for tableting, etc. The acid-soluble polymers are blended in an amount of &gt;=1, especially 10-10000 times based on the vitamin D. Although the vitamin D is useful as a therapeutic agent for osteopathy such as rachitis or osteromalacia, it is unstable to heat and light and cannot be preserved for a long period even by preparation into the pharmaceutical. Thereby, the disadvantages are improved to prepare a stable vitamin D pharmaceutical.
All  Borrelia burgdorferi  sensu lato isolates characterized to date have one or a combination of several major outer surface proteins (Osp). Mutants of  B. burgdorferi  lacking Osp proteins were selected with polyclonal or monoclonal antibodies at a frequency of 10 −6  to 10 −5 . One mutant that lacked OspA, B, C and D was further characterized in the present study. It was distinguished from the OspA + B +  cells by its (i) auto-aggregation and slower growth rate, (ii) decreased plating efficiency on solid medium, (iii) serum- and complement-sensitivity, and (iv) diminished capacity to adhere to human umbilical vein endothelial cells. The Osp-less mutant was unable to evoke a detectable immune response after intradermal live cell immunization even though mutant survived in the skin the same duration as wild-type cells. Polyclonal mouse serum raised against Osp-less cells inhibited growth of the mutant but not of wild-type cells, an indication that other antigens are present on the surface of the Osp-less mutant. Two different classes, A and B, of monoclonal antibodies (mAb) with growth inhibiting properties for mutant cells were produced. Class A mAbs bound to 13 kDa surface proteins of  B. burgdorferi  sensu stricto and of  B. afzelii.  The minimum inhibitory concentration of the Fab fragment of one mAb of this class was 0.2 μg/ml. Class B mAbs did not bind by Western Blot to  B. burgdorferi  cells but reacted with cells in an unfixed cell immunofluorescence assay and growth inhibition assay. These studies revealed hitherto unknown functional aspects of Osp proteins, notably serum-resistance, and indicated that in the absence of Osp proteins other antigens are expressed or become accessible at the cell&#39;s surface.
A method and an apparatus for determining at least one smoothed data point (t k , s k ) within a stream of data points {t i , s i } with 1≤i≤z, k&lt;z is disclosed. Herein, the stream of data points {t i , s i } is consecutively acquired in a manner that a data point (t i , s i ) is acquired after an acquisition of a preceding data point (t i−1 , s i−1 ), wherein each data point (t i , s i ) comprises a valid value or an invalid value or a missing value for the signal s i  at a time t i . Herein, the signal s i  at the time t i  comprises physical, chemical, biological, environmental, and/or technical data acquired by means of a technical set-up. According to the method, a set of data points is provided, wherein for each smoothed data point (t k , s k ) a smoothing set is created. For each smoothed data point (t k , s k ), trailing data resulting from large gaps are removed until it is verified whether the smoothing set comprises a minimal number of data points. Thereafter, for each smoothed data point (t k , s k ) an initial slope set is calculated, on which at least one exponential smoothing is applied, in which cause an at least once modified slope set is determined. By integrating the at least once modified slope set, a value for the smoothed data point (t k , s k ) is determined and returned. The method provides a good degree of smoothing without introducing any lag time and with minimal distortions, and is capable of reporting derivatives for the set of smoothed data points at the same time. The method is particularly suited in real-time or nearly real-time measurements which may comprise large gaps within the stream of data points.
This twenty-step business process uses a clinical trials matching system to perform scalable searches of derived patient data records for patients that may be eligible for clinical trials. The patent-bearing business contracts with healthcare providers of patients found in derived patient data records to review the likely matches of those patients to clinical trials. Contracted healthcare providers also provide sufficient data for the patent-bearing business to determine if their patients qualify for clinical trials. Probabilistic matching techniques are used for this determination. The healthcare provider solicits qualified patients for clinical trials and interacts to enroll patients in trials. Solicitation is active in that the patent bearing business need not wait for a patient to initiate contact in order to seek determination of a patient&#39;s potential eligibility to participate in a clinical trial. Patient privacy is protected by limiting patient contact to be only through the patient&#39;s healthcare provider.
PURPOSE:To obtain a composition for the oral cavity excellent in palatability without impairing carious inhibitory effects, by blending common salt containing a fluorine compound with other ingredients. CONSTITUTION:The objective substance obtained by blending and mixing 5-35wt.% common salt containing a fluorine compound in an amount of 0.1-10wt.% expressed in terms of fluorine therein with a normally used polishing agent, wetting agent, binder, surfactant, sweetener, perfume, etc., according to a conventional method. The content of the fluorine in the composition is preferably 500-3,000ppm. The common salt, classified by a sieve, etc., and having &gt;=100mum grain diameter is used. The fluorine is stably present in the water-insoluble common salt grains in a state of preservation by blending the granular common salt. The common salt grains are dissolved in use and stably present in a state of fluoride ions.
PROBLEM TO BE SOLVED: To provide a new compound that is useful in the treatment of central nervous system disorder. SOLUTION: This compound is represented by formula I (n, m are each 1, 2; p is 1-6; q is 0, 1-3; R&lt;1&gt; and R&lt;2&gt; are each H or the like; R&lt;3&gt; to R&lt;5&gt; are each H or the like; R&lt;6&gt; is a 1-4C alkyl; dotted line means a double bond; F bonds to the 6 or 7 position), its salt or ester, typically a compound of formula II. This new compound is obtained by reaction of a compound of formula III with an aldehyde equivalent of formula IV (X is a halogen). The aldehyde is prepared by oxidizing a suitable terminal alkene with ozone or the like followed by reductive amination of the aldehyde group with sodium cyanoborohydride or using triacetoxycyanoborohydride and a compound of formula III, preferably in a polar solvent as acetonitrile in the presence of a base as sodium iodide at 50-150 deg.C. The new compound of formula I has an effective action of activating the central nervous system.  The daily dose for treating an adult person is 0.5-100 mg.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a floating alga degradation product which is suitable as a food or drink composition or a food or drink additive.  &lt;P&gt;SOLUTION: A new bacterium having more excellent alga-degrading activity than those of known bacteria has been discovered. Preferably, the bacterium having the alga-degrading activity is a bacterium belonging to Alteromonas. More preferably, the bacterium is a bacterium having a 16S rRNA sequence composed of a characteristic nucleic acid sequence. Most preferably, the bacterium is Alteromonas 6532B2 strain (Accession number FERM AP-21070).  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To advertise medicine, medical material, and examination to a doctor at a pinpoint timing.  &lt;P&gt;SOLUTION: A computer system having the following three functions has been invented. First, there is provided the computer system in which, by efficiently employing the characteristic of an electronic medical record that a doctor directly inputs the medical records therein, as soon as the doctor starts a treatment, in accordance with the input disease name, an advertisement frame is displayed regarding medicine, medical material, and examination on a screen of the electronic medical record. Second, there is provided the computer system which automatically takes a step not to display a medicine in the advertisement frame even when the advertisement is reserved, when a medicine is incompatible with a disease name or a medicine. Third, there is provided the computer system in which, when a certain period of time passes with no input, until a next input event of any kind is generated, the electronic medical record screen is switched to display an advertisement of medicine, medical material, and examination which are not conscious of a disease name of a specified patient.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
To provide vehicles for controlled delivery of different pharmaceutical agents.SOLUTION: A &#34;nanolipogel&#34; is a delivery vehicle including one or more lipid layer surrounding a hydrogel core, which may include an absorbent such as a cyclodextrin or ion-exchange resin. Nanolipogels can be constructed so as to incorporate a variety of different chemical entities that can subsequently be released in a controlled fashion. These different incorporated chemical entities can differ dramatically with respect to size and composition. Nanolipogels have been constructed to contain co-encapsulated proteins as well as small hydrophobic drugs within the interior of the lipid bilayer. Agents incorporated within nanolipogels can be released into the milieu in a controlled fashion, for example, nanolipogels provide a means of achieving simultaneous sustained release of agents that differ widely in chemical composition and molecular weight. Additionally, nanolipogels can favorably modulate biodistribution.SELECTED DRAWING: None
PURPOSE:To suppress an objective error to an irreducible minimum in a short time when a change in the lapse of time in the capacity of the left ventricle is measured by executing approximation for the outline of the ventricle in each picture and measuring the capacity of the ventricle by using a conventional density method after the approximated outline is obtained. CONSTITUTION:A left ventricle capacity measuring means CPU 1 equally divides a distance mutually between the outlines of the both left ventricles in an extension end (ED), which is set in advance, of the left ventricle and a shrinkage end (ES) by a number, for which &#39;1&#39; is added to a picture (intermediate picture) from the ED to ES by using the picture, which is stored to a digital picture storage device 3, for the left ventricle of the heart. Then, the approximation of the outline of the left ventricle is executed concerning each intermediate picture by a straight line connecting the respective equal dividing points. The approximation is samely executed by the straight line for the set outline of the left ventricle in the ED picture. Then, the obtained respective approximated outlines of the left ventricle are regarded as the outlines of those pictures and the capacity of the left ventricle is calculated concerning each picture. After that, a curved line for the change in the lapse of time is displayed on a TV monitor 4. Thus, the objective error can be suppressed to the irreducible minimum and in such a case, the outline is set by an operator only concerning the two pictures of the ED and ES. Then, operation is made easy and speedy in comparison with conventional technique.
Procedure for obtaining lipopeptides. Consists of the following stages: 1. &#34;coupling&#34; between the N-carbobenzo-lencina and the amina rental. By the method of mixed anhydride with isobutil-chloroformate in tetrahydrofuran medium. Once the derived carbobenzoxi is purified, it is hydrogenated catalytically in the presence of black paladio. 2. Reaction of l-phenylalanin with N-hydroxisuccinimidic ester of N-carbobenzoxi glycine in dioxane/oh. 3. The tripeptide is hydrogenated and reacted with N-hydroxisuccinimidic ester in dioxan/oh medium. 4. Hydrogenation of the tripeptide obtained and reaction with ester N-hydroxisuccinimidico in dioxanal medium with agitation at ambient temperature. 5. Hydrogenation of the derivatives of the first stage and reaction with the previous tetrapeptide, using diclohexil carbodiimide as a coupling agent. The lipopeptides obtained are hydrogened and purified in silica column eluing with chloroform methanol. (Machine-translation by Google Translate, not legally binding)
Compositions for delivering materials, such as a biological material, sand, soil, metal, water, sea water, holy water, synthetic or biological polymers, cremated ash, ceramics, animal or plant tissue, or another physiologically compatible component having personal significance to an individual are described herein. The material(s) are encapsulated in an inert, non-bioerodible, hydrophobic, polymeric material. Methods of making microparticles encapsulating the personalizing substance and methods of use are also provided. The personalizing substance may be encapsulated in a polymeric non-bioerodible microparticle. The encapsulated personalizing substance may be combined with a carrier for delivery to an individual&#39;s skin. In some embodiments, the personalizing substance is added to a tattoo ink and incorporated in a tattoo created on an individual&#39;s skin. Following injection in the skin, the encapsulated material remains in the microparticles, and is not released over time.
PURPOSE:To easily obtain a liquid showing beautiful pearly gloss by mixing a dispersion liquid of fatty acid glycol ester to be used as crystal seeds and a solution of fatty acid glycol ester. CONSTITUTION:A dispersion liquid of pearly glossing agent having low concn. is prepared so that the liquid contains 0.1 - 5wt.% fatty acid glycol ester as crystal seeds. And a high-concn. pearly solution is prepared so that the soln. contains 15 - 65wt.% fatty acid glycol ester and 13 - 60wt.% surfactant. Both liquids are mixed and aged at such temp. lower than the melting point of the fatty acid glycol ester and that the high-concn. soln. does not solidify but uniformly grows, and under the average shearing rate of &lt;=7sec&lt;-1&gt;. After the crystal seeds grow, the liquid is cooled under low shearing force. Thereby, a high-concn. dispersion liquid showing beautiful pearly gloss and having uniform crystal size and good dispersibility can easily and surely be obtained.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a novel system having no shortcoming of an existing bleaching method for dying keratin materials, in particular human keratin fibers, especially dark hair.  &lt;P&gt;SOLUTION: A hemicyanine styryl thiol or disulfide dye is used for dyeing keratin materials. The dye composition comprising the hemicyanine styryl chromophore thiol or disulfide dye is used for a dyeing method with a lightening effect on keratin materials, in particular keratin fibers, especially human keratin fibers such as the hair. Similarly, a novel hemicyanine styryl chromophore thiol dye and its use in lightening keratin materials are also provided. The composition allows coloring with a durable and visible lightening effect on dark keratin fibers especially.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The present invention is a system and method for allowing an individual to view a program remotely. In the preferred embodiment, the invention is used as a healthcare education system. The system comprises a file server which is coupled to a database storing the educational programs. A remote interface coupled to the file server allows an administrator to assign educational programs to an individual. The remote interface also includes a memory card writer which records the individual identification code and the address of the file server on this memory card. Then, the individual may take the memory card with them. When the individual places the memory card in the memory card reader of a multimedia processor, the processor uses the file server address to automatically connect to the file server. The file server receives the individual identification code from the processor, retrieves the corresponding educational program from the database, and sends the program to the processor to be displayed. After the individual has watched the educational program, completion data in the form of the date and time the program was watched and/or the individual&#39;s response, is sent from the multimedia processor to the file server. The completion data can then be viewed by the administrator on a report screen.
Use of a histamine H2 mimicking substance for the manufacture of a medicament for the treatment of multiple sclerosis. The histamine H2 mimicking agent is present in an amount which is effective to stimulate production of a cyclic AMP in the body. A phosphodiesterase inhibitor is used in conjunction with the histamine H2 mimicking agent to conserve the cyclic AMP which is thus produced. It is believed that the increased cyclic AMP levels serve to maintain the patient&#39;s myeline against self degeneration. The histamine H2 mimicking agent may be histamine phosphate and the phosphodiesterase inhibitor may be caffeine.  The histamine H2 mimicking agent and the phosphodiesterase inhibitor may be mixed in a gel and administered using a transdermal patch.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cold sense agent composition imparting a sufficient refrigerant feeling without an irritant feeling over a long period and a cold sense cosmetic using the cold sense agent composition.  &lt;P&gt;SOLUTION: The cold sense agent composition is characterized as formulating 100 pts. of menthol with 1-30 pts. of isopulegol, 0.1-10 pts. of camphor, 1-30 pts. of monoglycol salicylate and 10-200 pts. of a skin penetrant. For further detail, the skin penetrant is one or more kinds of substances selected from diisopropyl adipate, diisopropyl sebacate and diethyl sebacate. The cold sense cosmetic comprises 0.1-50% of the cold sense agent composition.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI